Ipsen's pancreatic cancer drug bests decade-old standard of care

Kyle LaHucik

Senior Reporter

Ipsen’s cancer drug Onivyde, when combined with chemotherapy, performed better than standard of care at extending the lives of patients with a certain pancreatic cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ipsen's pancreatic cancer drug bests decade-old standard of care

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

Sofinnova outlines $550M fund after IPOs and M&A deals

Ipsen's pan­cre­at­ic can­cer drug bests decade-old stan­dard of care

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ipsen's pancreatic cancer drug bests decade-old standard of care

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

Sofinnova outlines $550M fund after IPOs and M&A deals